vs
Side-by-side financial comparison of Cellectis S.A. (CLLS) and NextPlat Corp (NXPL). Click either name above to swap in a different company.
NextPlat Corp is the larger business by last-quarter revenue ($12.8M vs $9.5M, roughly 1.3× Cellectis S.A.). NextPlat Corp runs the higher net margin — -40.2% vs -265.9%, a 225.7% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs -21.1%). Cellectis S.A. produced more free cash flow last quarter ($27.6M vs $-339.0K).
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
CLLS vs NXPL — Head-to-Head
Income Statement — Q2 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $12.8M |
| Net Profit | $-25.3M | $-5.1M |
| Gross Margin | — | 14.3% |
| Operating Margin | -181.1% | -28.9% |
| Net Margin | -265.9% | -40.2% |
| Revenue YoY | 375.0% | -21.1% |
| Net Profit YoY | -51.9% | -70.6% |
| EPS (diluted) | $-0.28 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $13.8M | ||
| Q2 25 | — | $13.2M | ||
| Q1 25 | — | $14.5M | ||
| Q4 24 | — | $16.2M | ||
| Q3 24 | — | $15.4M | ||
| Q2 24 | $9.5M | $17.0M | ||
| Q1 24 | — | $17.5M |
| Q4 25 | — | $-5.1M | ||
| Q3 25 | — | $-2.2M | ||
| Q2 25 | — | $-1.8M | ||
| Q1 25 | — | $-1.3M | ||
| Q4 24 | — | $-3.0M | ||
| Q3 24 | — | $-4.2M | ||
| Q2 24 | $-25.3M | $-5.3M | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | — | 14.3% | ||
| Q3 25 | — | 19.9% | ||
| Q2 25 | — | 21.8% | ||
| Q1 25 | — | 23.8% | ||
| Q4 24 | — | 16.8% | ||
| Q3 24 | — | 23.2% | ||
| Q2 24 | — | 34.5% | ||
| Q1 24 | — | 27.8% |
| Q4 25 | — | -28.9% | ||
| Q3 25 | — | -14.5% | ||
| Q2 25 | — | -13.8% | ||
| Q1 25 | — | -10.2% | ||
| Q4 24 | — | -14.1% | ||
| Q3 24 | — | -52.1% | ||
| Q2 24 | -181.1% | -64.1% | ||
| Q1 24 | — | -10.5% |
| Q4 25 | — | -40.2% | ||
| Q3 25 | — | -15.9% | ||
| Q2 25 | — | -13.5% | ||
| Q1 25 | — | -9.2% | ||
| Q4 24 | — | -18.6% | ||
| Q3 24 | — | -27.4% | ||
| Q2 24 | -265.9% | -31.3% | ||
| Q1 24 | — | -8.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.22 | ||
| Q2 24 | $-0.28 | — | ||
| Q1 24 | — | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $149.0M | $13.7M |
| Total DebtLower is stronger | — | $1.3M |
| Stockholders' EquityBook value | $148.6M | $17.3M |
| Total Assets | $407.1M | $27.5M |
| Debt / EquityLower = less leverage | — | 0.07× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $13.7M | ||
| Q3 25 | — | $13.9M | ||
| Q2 25 | — | $16.6M | ||
| Q1 25 | — | $17.7M | ||
| Q4 24 | — | $20.0M | ||
| Q3 24 | — | $20.4M | ||
| Q2 24 | $149.0M | $24.9M | ||
| Q1 24 | — | $23.5M |
| Q4 25 | — | $1.3M | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | — | $1.3M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | — | $1.5M | ||
| Q2 24 | — | $1.3M | ||
| Q1 24 | — | $1.4M |
| Q4 25 | — | $17.3M | ||
| Q3 25 | — | $21.4M | ||
| Q2 25 | — | $23.5M | ||
| Q1 25 | — | $25.3M | ||
| Q4 24 | — | $27.3M | ||
| Q3 24 | — | $22.5M | ||
| Q2 24 | $148.6M | $26.5M | ||
| Q1 24 | — | $31.2M |
| Q4 25 | — | $27.5M | ||
| Q3 25 | — | $30.0M | ||
| Q2 25 | — | $31.0M | ||
| Q1 25 | — | $35.2M | ||
| Q4 24 | — | $37.1M | ||
| Q3 24 | — | $41.1M | ||
| Q2 24 | $407.1M | $51.5M | ||
| Q1 24 | — | $65.1M |
| Q4 25 | — | 0.07× | ||
| Q3 25 | — | 0.05× | ||
| Q2 25 | — | 0.05× | ||
| Q1 25 | — | 0.05× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 0.05× | ||
| Q1 24 | — | 0.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.9M | $-302.0K |
| Free Cash FlowOCF − Capex | $27.6M | $-339.0K |
| FCF MarginFCF / Revenue | 290.5% | -2.6% |
| Capex IntensityCapex / Revenue | 13.2% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-302.0K | ||
| Q3 25 | — | $-2.7M | ||
| Q2 25 | — | $-1.0M | ||
| Q1 25 | — | $-2.1M | ||
| Q4 24 | — | $-476.0K | ||
| Q3 24 | — | $-4.6M | ||
| Q2 24 | $28.9M | $2.3M | ||
| Q1 24 | — | $-2.7M |
| Q4 25 | — | $-339.0K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-1.1M | ||
| Q1 25 | — | $-2.1M | ||
| Q4 24 | — | $-508.0K | ||
| Q3 24 | — | $-4.7M | ||
| Q2 24 | $27.6M | $2.2M | ||
| Q1 24 | — | $-2.7M |
| Q4 25 | — | -2.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -8.0% | ||
| Q1 25 | — | -14.3% | ||
| Q4 24 | — | -3.1% | ||
| Q3 24 | — | -30.6% | ||
| Q2 24 | 290.5% | 13.2% | ||
| Q1 24 | — | -15.7% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | 13.2% | 0.4% | ||
| Q1 24 | — | 0.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLLS
Segment breakdown not available.
NXPL
| Healthcare Operations | $9.0M | 70% |
| Ecommerce Revenue | $3.8M | 30% |
